Adma Biologics Inc P/FCF
What is the P/FCF of Adma Biologics Inc?
The P/FCF of Adma Biologics Inc is 10.46
What is the definition of P/FCF?
Price to free cash flow (P/FCF) is a valuation metric that compares the company’s current share price to its free cash flow per share.
ttm (trailing twelve months)
Price to free cash flow (P/FCF) is a measure that value investors find useful to analyze a company’s finances in relation to its current stock price. It is a stricter measure than the price to cash flow ratio as it subtracts capital expenditures from cash flow.
Free cash flow relies heavily on the state of a company's cash from operations, which is in turn heavily influenced by the company's net income. Companies can manipulate their free cash flow by lengthening the time they take to pay their bills, shortening the time it takes to collect what's owed to them, and putting off buying inventory. It also depends on what items are considered capital expenditures and this can be different in case of different companies.
Lower values of P/FCF generally indicate a company that is undervalued and whose stock is relatively cheap in relation to its free cash flow. Conversely, higher P/FCF indicate that the company's stock is relatively overvalued. Value investors thus favor companies with low or decreasing price to free cash flow values that indicate high or increasing free cash flow totals and relatively low stock share prices.
It is best to compare price to free cash flow ratios between similar companies in the same industry. However, the P/FCF metric can also be viewed over a longer time frame to see if the company's cash flow to share price value is improving or declining.
P/FCF of companies in the Health Care sector on NASDAQ compared to Adma Biologics Inc
What does Adma Biologics Inc do?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Companies with p/fcf similar to Adma Biologics Inc
- People's Utah Bancorp has P/FCF of 10.45
- Kingkey International () has P/FCF of 10.45
- Alerus has P/FCF of 10.45
- Alerus has P/FCF of 10.45
- Alerus has P/FCF of 10.45
- Alerus has P/FCF of 10.45
- Adma Biologics Inc has P/FCF of 10.46
- Live Nation Entertainment has P/FCF of 10.47
- Hub has P/FCF of 10.47
- Public Joint Stock Mining and Metallurgical Norilsk Nickel has P/FCF of 10.47
- Samsonite International SA has P/FCF of 10.47
- Buckle has P/FCF of 10.47
- Samsonite International SA has P/FCF of 10.47